REMS Vendor Disruptions Prompt Greater US FDA Scrutiny

 
• By Brenda Sandburg
  
Vendor
Switching third-party vendors that manage REMS programs can disrupt patient access to a drug • Source: Shutterstock

More from Drug Safety

More from Pink Sheet